Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Genevant Sciences","sponsor":"2Seventy Bio","pharmaFlowCategory":"D","amount":"$40.0 million","upfrontCash":"$5.0 million","newsHeadline":"2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Genevant Sciences"},{"company":"Virica Biotech","sponsor":"Innovation, Science and Economic Development Canada","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Virica Biotech Announces Collaboration with the Government of Canada","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Undisclosed","country":"CANADA","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Virica Biotech"}]

Virica Biotech

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Virica Biotech Announces Collaboration with the Government of Canada

Details:

Funding supports Virica’s collaboration with the National Research Council of Canada’s Cell and Gene Therapy Challenge program to enhance the manufacturing of an affordable, AAV-LPL, a gene therapy being developed for people with debilitating lipoprotein lipase deficiency.

Lead Product(s): Re-engineered AAV-LPL

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Innovation, Science and Economic Development Canada

Deal Size: $0.4 million Upfront Cash: Undisclosed

Deal Type: Collaboration May 02, 2022

ASK
US

Upload
your Pipeline Activity

Genevant Sciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Editing Approach

Details:

Under the terms of the agreement between 2seventy bio and Genevant, 2seventy bio obtained rights to license Genevant’s LNP technology for use with megaTAL mRNA products in the treatment of patients with hemophilia A.

Lead Product(s): MegaTAL mRNA

Therapeutic Area: Genetic Disease Product Name: MegaTAL mRNA

Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: 2Seventy Bio

Deal Size: $40.0 million Upfront Cash: $5.0 million

Deal Type: Licensing Agreement January 06, 2022

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY